WCN26-2449 EFFECTS OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITOR ON CHRONIC eGFR SLOPES IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A REAL WORLD DATA

Read full text Summarise with VIRAT
Authors: Ai ISOBE, Hiroki Uchida, Hikaru Tanaka, Sayaka Abe, Makoto Ando, Chisato Mitsue, Ryo Kurimoto, Misaki Maruo, Miho Suzuki, Yuko Yamasaki, Akiko Kudo, Takeshi Nakata
+2 more Akihiro Fukuda, Hirotaka Shibata
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Numerous clinical trials have reported renoprotective effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors, slowing progression to end-stage kidney disease in patients with diabetic kidney disease (DKD). Additionally, some studies have reported renoprotective effects in patients with non-diabetic kidney disease (non-DKD). To date, studies evaluating the effects of SGLT2 inhibitors in both DKD and non-DKD patients in clinical practice remain insufficient. In this study, we investigated the effects of SGLT2 inhibitors on eGFR trajectory in CKD patients with and without DKD.

Fields of Study & Subjects

Chronic Kidney Disease and Diabetes Diabetes Treatment and Management Acute Kidney Injury Research

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104593–104593
Publication date
25 March 2026
Language
EN